04 Oct, EOD - Indian

SENSEX 81688.45 (-0.98)

Nifty 50 25014.6 (-0.93)

Nifty Bank 51462.05 (-0.74)

Nifty IT 41912.5 (0.36)

Nifty Midcap 100 58474.45 (-0.93)

Nifty Next 50 74620.25 (-1.10)

Nifty Pharma 23094.7 (-0.36)

Nifty Smallcap 100 18758.65 (-1.02)

04 Oct, EOD - Global

NIKKEI 225 38635.62 (0.22)

HANG SENG 22736.87 (2.82)

S&P 5807.5 (0.80)

Login/Signup
LOGIN HERE
Cancel

You are Here : Home > Markets > CompanyInformation > Board Meeting
BSE Code : | NSE Symbol : | ISIN : | Industry : |


Board Meeting
Announcement Date Date Of Meeting Purpose Detail
27-Aug-2024 04-Sep-2024 Acquisitions Remedium Lifecare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/09/2024 inter alia to consider and approve 1. Acquisition of a company Airowater Global Trading LLC UAE which is into Water Injectables for Pharma Production. 2. Consideration of issuing of Foreign Currency Convertible Bonds (FCCBs) 3. Any other business with the permission of the Chair The Board Meeting to be held on 03/09/2024 has been revised to 04/09/2024 The Board Meeting to be held on 03/09/2024 has been revised to 04/09/2024 inter alia 1. To Consider Acquisition of AirOWater Global Trading LLC, UAE:The Board will review the proposal to acquire a substantial stake in AirOWater Global Trading LLC, a pioneering entity in the production of the purest form of drinking water via Atmospheric Water Generators (AWGs). This technology, recognised as one of the most sustainable solutions to the pressing issue of global water scarcity, has successfully catered to diverse sectors including Government Institutions, Corporates, Hospitality chains, Supermarkets, Hospital chains, Educational institutions, and Community Centres. 2. To Consider issuing of Foreign Currency Convertible Bonds (FCCBs). 3. Any other business with the permission of the Chair. (As per BSE Announcement Dated on 28/08/2024)
15-Jul-2024 14-Aug-2024 Quarterly Results Remedium Lifecare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2024 inter alia to consider and approve 1) Consideration And Approval Of The Unaudited Financial Results For The Quarter Ended 30th June 2024. 2) Consideration of acquisition of an unlisted company in the specialty chemicals sector with a global footprint. 3) Authorise the board to approve the transaction structure valuation and timelines given the preliminary nature of the discussions. 4) Ratify the transaction in a subsequent Extraordinary General Meeting (EGM) or through Postal Ballot. The Board Meeting to be held on 08/08/2024 has been revised to 14/08/2024 The Board Meeting to be held on 08/08/2024 has been revised to 14/08/2024 (As per BSE Announcement Dated on 07/08/2024) With reference to the captioned subject and our announcement dated August 14, 2024, please find below corrigendum to the outcome of Board Meeting. 1. In the said announcement, in body of covering letter while uploading on BSE in corporate announcement it is incorrectly mentioned as meeting held on August 12, 2023 instead of meeting held on August 14, 2024. The Date of said Board Meeting is August 14, 2024, kindly read it as August 14, 2024. 2. In Body of covering letter while uploading on BSE in corporate announcement it is incorrectly mentioned as Financial Result for quarter ended June 30, 2023 instead of Financial Result for quarter ended June 30, 2024. The said result is pertaining to Financial Result for quarter ended June 30, 2024, kindly read it as Financial Result for quarter ended June 30, 2024. Read less.. (As Per BSE Announcement Dated on 16.08.2024)
17-Jul-2024 20-Jul-2024 Increase in Authorised Capital Remedium Lifecare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/07/2024 inter alia to consider and approve 1) Increase in Authorized Capital of the Company and consequent alteration in Capital Clause of the Memorandum of Association of the Company. 2) To consider & approve the Draft Postal Ballot Notice of the Company and fixing of date of Book closure and e-voting period 3) To appoint Scrutinizer for conducting E- voting process. 4) Any other business with the permission of the Chair 1) increase in Authorized Share Capital of the Company from Rs. 42,00,00,000/- (Rupees Forty Two Crores Only) divided into 42,00,00,000 (Forty Two Crores) Equity Shares of Re. 1/- (Rupee One Only) each to Rs. 60,00,00,000/- (Rupees Sixty Crores Only) divided into 60,00,00,000 (Sixty Crores Only) Equity Shares of Re. 1/- (Rupee One Only) each and consequent Alteration in Capital Clause of the Memorandum of Association of the Company. 2) Approved Draft Postal Ballot Notice pursuant to Section 110 of the Companies Act, 2013 and other applicable provisions 3) appointment of Scrutinizer for conducting Postal Ballot 4) Cut Off date for determining shareholders eligible to vote. (As per BSE Announcement Dated on 20/07/2024)
02-Jul-2024 08-Jul-2024 Raising funds through Debt Instr. Remedium Lifecare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/07/2024 inter alia to consider and approve Intimation of the Board Meeting under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 Outcome of Board Meeting dated July 08, 2024: 1. Fund Raising through Qualified Institutional Placement (QIP) 2. Allotment of Bonus Shares Kindly take the above on record. (As per BSE Announcement Dated on 08/07/2024)
02-May-2024 27-May-2024 Accounts Remedium Lifecare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/05/2024 inter alia to consider and approve Audited Financial Results for the quarter and Financial Year ended 31st March 2024 and Consider Recommendation and approval of the issue of Bonus Shares to the existing Equity Shareholders of the Company. The Board Meeting to be held on 10/05/2024 has been revised to 27/05/2024 The Board Meeting to be held on 10/05/2024 has been revised to 27/05/2024 (As per BSE Announcement Dated on 09/05/2024) 1. Financial Results for the quarter and year ended March 31st, 2024 2. issue of Bonus shares (As per BSE Announcement Dated on 27/05/2024)
12-Apr-2024 12-Apr-2024 Change in Auditors In terms of Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015, cessation of Dr. Maneesha Naresh, current term of office is completed and she would not be able to continue for another term. Appointment of Internal Auditor and Secretarial Auditor
23-Feb-2024 07-Mar-2024 Acquisitions Remedium Lifecare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/03/2024 inter alia to consider and approve Intimation of Board Meeting inter alia to consider acquisition of manufacturing facility near hyderabad producing intermediates for the Pharmaceutical Industry. This is to inform you that the Board of Directors of the Company at its meeting has proposed to acquire a Manufacturing Facility in Hyderabad situated at Phase 2, Survey No.10, Gaddapotharam Industrial Area, Jinnaram Mandal, Medak, Sangareddy District, Hyderabad-502319, Telangana, India. having an area of 130680 square feet. The unit is well equipped to produce Intermediates for the Pharmaceutical Industry. (As Per BSE Announcement dated on 07.03.2024)
06-Feb-2024 14-Feb-2024 Quarterly Results Remedium Lifecare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2024 inter alia to consider and approve the Unaudited Financial Results for quarter & nine months ended December 31 2023. Approval of Financial Result on Board Meeting held on Wednesday, February 14, 2024 (As Per BSE Announcement Dated on: 14/02/2024)
02-Jan-2024 08-Jan-2024 Stock Split Remedium Lifecare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/01/2024 inter alia to consider and approve sub-division of shares/ stock split of the company. Outcome for Outcome Of The Board Meeting 1. Sub-division (stock split) of every 1(one) equity share of face value Rs. 5/- each into 5 (five) equity share of face value of Re.1/- 2.Alteration of Capital clause of the Memorandum of Association of the Company consequent upon sub-division/ stock split 3.Appointment of Mr. Adarsh Munjal (DIN: 073040004) Whole-time Director 4. Approval of draft Postal Ballot Notice. 5. Appointment of Scrutinizer. 1. Sub-division (stock split) of every 1(one) equity share of face value Rs. 5/- each into 5 (five) equity share of face value of Re.1/- 2.Alteration of Capital clause of the Memorandum of Association of the Company consequent upon sub-division/ stock split 3.Appointment of Mr. Adarsh Munjal (DIN: 073040004) Whole-time Director 4. Approval of draft Postal Ballot Notice. 5. Appointment of Scrutinizer. (As Per BSE Announcement Dated on 08.01.2024)
04-Nov-2023 11-Nov-2023 Quarterly Results Remedium Lifecare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2023 inter alia to consider and approve the Unaudited Financial Results for the quarter and half year ended 30th September 2023. Board Meeting Outcome for Unaudited Financial Results For The Quarter And Half Year Ended 30.09.2023 Unaudited Financial Results for the quarter and half year ending 30.09.2023 (As Per BSE Announcement dated on 11.11.2023)
26-Aug-2023 05-Sep-2023 Change in Directors Remedium Lifecare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/09/2023 inter alia to consider and approve Remedium Lifecare Limited has informed BSE that the meeting of the Board of Directors of the Company is scheduled to be held on Tuesday September 05 2023 inter alia to transact the following business: 1. To appoint Mr. Adarsh Deepak Munjal (DIN: 07304004) as a Whole Time Director of the Company for a period of 3 years w.e.f. 05.09.2023 subject to the approval of the shareholders at the ensuing Extra Ordinary General Meeting of the company. 2. To consider and take on record the resignation of Dr. Vilas Ramkrishna Lokhande (DIN: 01228041) from the position of Whole Time Director of the Company. 3. Any other matter with the permission of the chair. Outcome of the Board Meeting held on 05.09.2023 (As Per BSE Announcement Dated on 05.09.2023)
03-Aug-2023 12-Aug-2023 Quarterly Results Remedium Lifecare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2023 inter alia to consider and approve the Un-Audited Financial Results for the quarter ended June 30 2023. REMEDIUM LIFECARE LIMITED has informed BSE about Board Meeting to be held on 12 Aug 2023 to consider financial statements for the period ended June 2023. Financial results. Outcome of Board Meeting held on Saturday, August 12, 2023. (As per BSE Announcement Dated on 12/08/2023)
31-Jul-2023 31-Jul-2023 Bonus Issue We wish to inform you that our Company, Remedium Lifecare Limited ('the Company') in its Board Meeting held on July 31, 2023 have allotted 64,80,000 Equity Shares of Rs.10/-each as fully paid Bonus Shares to the existing shareholders of the Company as on record date July 29, 2023 in the ratio 9:5 ie. 9 (Nine) fully paid Equity shares for every 5 (Five) Equity shares held.
14-Jun-2023 23-Jun-2023 Stock Split Remedium Lifecare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/06/2023 inter alia to consider and approve 1. issue of Bonus Shares to the existing Equity Shareholders of the Company. 2. Sub-division of Shares/ Stock Split of the Company. 3. Increasing of borrowing limit from INR 50 Crores to INR 1000 Crores by issuance of debt securities ie. Non -Convertible Debentures(NCD) Bank Term Loans etc. 4. Limit for investment by way of acquisition of Asset such as Plant & Machinery securities etc upto INR 1000 Crores. Remedium Lifecare Ltd has informed BSE that the Board of Directors of the Company at their meeting held on 23/06/2023 ,inter alia, had considered and approved the: 1. Issue of Bonus Shares to the existing Equity Shareholders of the Company. 2. Sub-division of Shares/ Stock Split of the Company. 3. Board recommendation for seeking enabling resolution for borrowing in excess of limit specified u/s 180(1)(c) of the Companies act 2013 subject to shareholders approval. (As Per BSE Announcement dated on 23.06.2023)
23-May-2023 30-May-2023 Accounts Remedium Lifecare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2023 inter alia to consider and approve the Audited Financial Results for the quarter and Financial Year ended 31st March 2023. Outcome of Board Meeting held on 30.05.2023 The Board of Directors of the Company in its meeting held on 30th May, 2023, had taken up the discussion regarding status of approval for the Scheme of amalgamation between MVK Lifesciences Private Limited ('Transferor Company) and Remedium Lifecare Limited ('Transferee Company') and their respective shareholders ('the Scheme') filed with BSE India on 7th January, 2023. After due deliberation, the Board is of the view that it would be prudent to not proceed with the Scheme and keeping in mind the strategic interest, to explore other options to achieve the desired synergies. Accordingly, it has decided to withdraw the Scheme with immediate effect. (As Per BSE Announcement dated on 30.05.2023) The Board of Directors of the company at their meeting held on 30.05.2023, has approved the shifting of the registered office of the company from existing address at Office No. 601, Hyde Park, Saki Vihar Road, Andheri (E), Mumbai - 400 072 to Office No. 9, K Raheja Prime, Marol Industrial Estate, Behind Ravi Vihar Hotel, Saugbaug Road, Marol, Andheri (E), Mumbai - 400 059. (As Per BSE Announcement Dated on 31.05.2023)
1 2 3